摘要
摘要
INTRODUCTION: Immune checkpoint inhibitors targeting programmed death-1 (PD-1) in combination with tyrosine kinase inhibitors have reshaped the first-line treatment landscape of advanced renal cell carcinoma (RCC). However, the relative efficacy and safety of different PD-1-based regimens remain unclear. This meta-analysis aims to evaluate the efficacy and safety of first-line anti-PD-1-based combinations with tyrosine kinase inhibitors compared with sunitinib in metastatic RCC and to explore whether clinical outcomes differ according to the PD-1 inhibitor subtype. METHODS: We performed a systematic review and meta-analysis of phase III randomized controlled trials comparing anti-PD-1-based combinations (pembrolizumab + axitinib, pembrolizumab + lenvatinib, nivolumab + cabozantinib) vs sunitinib in treatment-naïve advanced RCC. HRs for overall survival (OS) and progression-free survival were pooled using random-effects models. Subgroup analyses were conducted according to PD-L1 status. RESULTS: Three pivotal trials enrolling 2224 patients were included. Anti-PD-1-based regimens significantly improved OS (pooled HR = 0.66, 95% CI 0.53-0.83) and progression-free survival (pooled HR = 0.56, 95% CI 0.47-0.67) compared with sunitinib, with consistent gains in objective response rate. Subgroup analyses showed benefit irrespective of programmed death ligand 1 (PD-L1) status: pooled HRs for OS were 0.54 (95% CI 0.42-0.68) in PD-L1-negative and 0.53 (95% CI 0.38-0.74) in PD-L1-positive tumors. CONCLUSIONS: First-line anti-PD-1-based immunotherapy combinations significantly improve survival and response outcomes over sunitinib in advanced RCC, with consistent efficacy across PD-1 subtypes and PD-L1 expression groups.
KM 提取结果
0 个 Figure · 0 个 KM 面板